U.S. court invalidates patent on Bristol hepatitis B drug
Feb 12 (Reuters) - A U.S. federal court has invalidated the patent on Bristol-Myers Squibb Co's Baraclude treatment for hepatitis B after a challenge from generic drugmaker Teva Pharmaceutical Industries Ltd, Bristol-Myers said on Tuesday.
"We are disappointed with the court's decision and believe it is incorrect," Bristol-Myers spokeswoman Laura Hortas said. She said her company is considering whether to appeal the ruling by the U.S. District Court in Delaware.
- Obama unveils U.S. immigration reform, setting up fight with Republicans |
- Officials make preparations for Ferguson grand jury decision |
- More arrests as protesters await Ferguson grand jury decision
- U.S., Iran discussing new ideas to break nuclear impasse: sources
- 'Immoral, but not illegal': metal warehousing games in the spotlight
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video